PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Risk & Volatility
PTC Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.85, suggesting that its stock price is 285% more volatile than the S&P 500.
Earnings & Valuation
This table compares PTC Therapeutics and GeoVax Labs”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $1.73 billion | 3.14 | $682.64 million | ($1.40) | -46.45 |
| GeoVax Labs | $2.49 million | 0.42 | -$21.47 million | ($11.34) | -0.01 |
PTC Therapeutics has higher revenue and earnings than GeoVax Labs. PTC Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares PTC Therapeutics and GeoVax Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | -9.17% | N/A | -0.10% |
| GeoVax Labs | N/A | -743.64% | -394.74% |
Institutional & Insider Ownership
6.1% of GeoVax Labs shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for PTC Therapeutics and GeoVax Labs, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 1 | 3 | 10 | 1 | 2.73 |
| GeoVax Labs | 1 | 1 | 1 | 0 | 2.00 |
PTC Therapeutics currently has a consensus target price of $99.23, suggesting a potential upside of 52.59%. GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 104,795.10%. Given GeoVax Labs’ higher probable upside, analysts clearly believe GeoVax Labs is more favorable than PTC Therapeutics.
Summary
PTC Therapeutics beats GeoVax Labs on 10 of the 15 factors compared between the two stocks.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
About GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
